Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
14 Novembre 2024 - 10:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 2)*
| Adverum
Biotechnologies, Inc. |
| (Name
of Issuer) |
| |
| Common
Stock, par value $0.0001 per share |
| (Title
of Class of Securities) |
| |
| 00773U207 |
| (CUSIP
Number) |
| |
| September
30, 2024 |
| (Date
of Event Which Requires Filing of this Statement) |
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☒
Rule 13d-1(c)
☐
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
| 1 |
NAME
OF REPORTING PERSONS
Commodore
Capital LP |
| 2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐ |
| 3 |
SEC
USE ONLY
|
|
| 4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware,
USA |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER
0 |
| 6 |
SHARED
VOTING POWER
0 |
| 7 |
SOLE
DISPOSITIVE POWER
0 |
| 8 |
SHARED
DISPOSITIVE POWER
0 |
| 9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
| 10 |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
☐ |
| 11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
| 12 |
TYPE
OF REPORTING PERSON
IA |
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
| 1 |
NAME
OF REPORTING PERSONS
Commodore
Capital Master LP |
| 2 |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐ |
| 3 |
SEC
USE ONLY
|
|
| 4 |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Cayman
Islands |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH |
5 |
SOLE
VOTING POWER
0 |
| 6 |
SHARED
VOTING POWER
0 |
| 7 |
SOLE
DISPOSITIVE POWER
0 |
| 8 |
SHARED
DISPOSITIVE POWER
0 |
| 9 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 |
| 10 |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
☐ |
| 11 |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% |
| 12 |
TYPE
OF REPORTING PERSON
OO |
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
| Item
1. |
(a)
Name of Issuer |
| |
|
| |
Adverum
Biotechnologies, Inc. (the “Issuer”) |
| |
|
| Item
1. |
(b)
Address of Issuer’s Principal Executive Offices |
| |
|
| |
100
Cardinal Way, Redwood City, California 94063 |
| |
|
| Item
2. |
(a,
b, c) Names of Person Filing, Address of Principal Business Office, Citizenship: |
| |
|
| |
This
report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore
Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore
Master is: 444 Madison Avenue, Floor 35, New York, New York 10022. |
| |
|
| Item
2. |
(d)
Title of Class of Securities |
| |
|
| |
Common
Stock, par value $0.0001 per share (the “Common Stock”) |
| |
|
| Item
2. |
(e)
CUSIP No.: |
| |
|
| |
00773U207 |
| |
|
| Item
3. |
If
this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a: |
| |
|
| |
N/A |
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
| Item
4. |
Ownership |
| |
|
| |
As
reported in the cover pages to this report, the ownership information with respect to the Firm is as follows: |
| |
|
| |
(a)
Amount Beneficially Owned: 0 |
| |
(b)
Percent of Class: 0% |
| |
(c)
Number of Shares as to which such person has: |
| |
(i)
Sole power to vote or to direct the vote: 0 |
| |
(ii)
Shared power to vote or to direct the vote: 0 |
| |
(iii)
Sole power to dispose or to direct the disposition of: 0 |
| |
(iv)
Shared power to dispose or to direct the disposition of: 0 |
As
reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:
(a)
Amount Beneficially Owned: 0
(b)
Percent of Class: 0%
(c)
Number of Shares as to which such person has:
| |
(i)
Sole power to vote or to direct the vote: 0 |
| |
(ii)
Shared power to vote or to direct the vote: 0 |
| |
(iii)
Sole power to dispose or to direct the disposition of: 0 |
| |
(iv)
Shared power to dispose or to direct the disposition of: 0 |
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
| Item
5. |
Ownership
of Five Percent or Less of a Class |
| |
|
| |
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following ☒. |
| |
|
| Item
6. |
Ownership
of More Than Five Percent on Behalf of Another Person |
| |
|
| |
Not
Applicable. |
| |
|
| Item
7. |
Identification
and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person |
| |
|
| |
Not
Applicable. |
| |
|
| Item
8. |
Identification
and Classification of Members of the Group |
| |
|
| |
Not
Applicable. |
| |
|
| Item
9. |
Notice
of Dissolution of Group |
| |
|
| |
Not
Applicable. |
| |
|
| Item
10. |
Certification |
| |
|
| |
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
Exhibit
Index
| CUSIP
No. 00773U207 |
SCHEDULE
13G |
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Dated:
November 14, 2024
| Commodore
Capital LP |
|
| |
|
| By: |
/s/
Michael Kramarz |
|
| Michael
Kramarz, Managing Partner |
|
| |
|
| Commodore
Capital Master LP |
|
| |
|
| By: |
/s/
Michael Kramarz |
|
| Michael
Kramarz, Authorized Signatory |
|
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Adverum Biotechnologies (NASDAQ:ADVM)
Storico
Da Nov 2023 a Nov 2024
